Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load

European Journal of Pharmacology

Volumn 651, Issue 1-3, 2011, Pages 240-250

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Ferrari, Ilaria ^a   Fogari, Elena ^a   D'Angelo, Angela ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Bianchi, Lucio ^a   Cicero, Arrigo Fg ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acarbose; Euglycemic hyperinsulinemic clamp; Inflammation; Oral fat load; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EXERCISE; FEMALE; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DIETARY FATS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED;

EID: 78650679019     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.11.015     Document Type: Article

References (48)

1. A. Alipour, J.W. Elte, H.C. van Zaanen, A.P. Rietveld, and M.C. Cabezas Postprandial inflammation and endothelial dysfunction Biochem. Soc. Trans. 35 2007 466 469
2. K. Asadollahi, N. Beeching, and G. Gill Hyperglycaemia and mortality J. R. Soc. Med. 100 2007 503 507
3. D.S. Bell, J.H. O'Keefe, and P. Jellinger Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr. Pract. 14 2008 112 124
4. M. Blüher, R. Unger, F. Rassoul, V. Richter, and R. Paschke Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes Diabetologia 45 2002 210 216
5. H.F. Bunn, K.H. Gabbay, and P.M. Gallop The glycosylation of haemoglobin. Relevance to diabetes mellitus Science 200 1978 21 27
6. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
7. J. Constans, and C. Conri Circulating markers of endothelial function in cardiovascular disease Clin. Chim. Acta 368 2006 33 47
8. DECODE Study Group the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria Arch. Intern. Med. 161 2001 397 405
9. R.A. De Fronzo, J.A. Tobin, and B. Andres Glucose clamp technique, a method for quantifying insulin secretion and resistance Am. J. Physiol. 237 1979 214 223
10. G. Derosa, A.F. Cicero, A. D'Angelo, P.D. Ragonesi, L. Ciccarelli, E. Fogari, S.A. Salvadeo, I. Ferrari, A. Gravina, R. Fassi, and R. Fogari Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance Clin. Drug Investig. 26 2006 529 539
11. G. Derosa, A. D'Angelo, S.A.T. Salvadeo, I. Ferrari, E. Fogari, A. Gravina, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F.G. Cicero Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment Biomed. Pharmacother. 63 2009 723 733
12. G. Derosa, I. Ferrari, A. D'Angelo, S.A. Salvadeo, E. Fogari, A. Gravina, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F. Cicero Oral fat load effects on inflammation and endothelial stress markers in healthy subjects Heart Vessels 24 2009 204 210
13. G. Derosa, S.A.T. Salvadeo, A. D'Angelo, I. Ferrari, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F.G. Cicero Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial Curr. Med. Res. Opin. 25 2009 607 615
14. G. Derosa, A. D'Angelo, S.A. Salvadeo, I. Ferrari, E. Fogari, A. Gravina, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F. Cicero Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects Microvasc. Res. 79 2010 144 149
15. G. Derosa, A. D'Angelo, S.A. Salvadeo, I. Ferrari, E. Fogari, A. Gravina, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F. Cicero Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients Horm. Metab. Res. 42 2010 8 13
16. G. Derosa, I. Ferrari, A. D'Angelo, S.A. Salvadeo, E. Fogari, A. Gravina, R. Mereu, I. Palumbo, P. Maffioli, S. Randazzo, and A.F. Cicero Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects Microvasc. Res. 80 2010 110 115
17. G. Derosa, P. Maffioli, S.A. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, I. Palumbo, A. D'Angelo, and A.F. Cicero Candesartan effect on inflammation in hypertension Hypertens. Res. 33 2010 209 213
18. G. Derosa, R. Mereu, A. D'Angelo, S.A. Salvadeo, I. Ferrari, E. Fogari, A. Gravina, I. Palumbo, P. Maffioli, S. Randazzo, and A.F.G. Cicero Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin J. Clin. Pharm. Ther. 35 2010 565 579
19. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabet. Med. 16 1999 716 730
20. E. Ferrannini, G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua Insulin resistance in essential hypertension N. Engl. J. Med. 317 1987 350 357
21. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge Clin. Chem. 18 1972 499 502
22. C.J. Halkes, H. van Dijk, P.P. de Jaegere, H.W. Plokker, Y. van Der Helm, D.W. Erkelens, and M. Castro Cabezas Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin Arterioscler. Thromb. Vasc. Biol. 21 2001 1526 1530
23. R.J. Havel, H.A. Edr, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 34 1955 1345 1353
24. L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
25. M. Jastrzebska, K. Przybycień, K. Chelstowski, B. Torbus-Lisiecka, Z. Kornacewicz-Jach, and M. Naruszewicz Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography Nutr. Metab. Cardiovasc. Dis. 9 1999 33 40
26. F. Karpe, G. Steiner, K. Uffelman, T. Olivecrona, and A. Hamsten Postprandial lipoproteins and progression of coronary atherosclerosis Atherosclerosis 106 1994 83 97
27. T. Kato, T. Inoue, and K. Node Post-prandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study Cardiovasc. Diabetol. 9 2010 12
28. S. Klose, and K. Borner Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II) J. Clin. Chem. Clin. Biochem. 15 1978 121 130
29. A.J. Krentz, and C.J. Bailey Oral antidiabetic agents. Current role in type 2 diabetes mellitus Drugs 65 2005 385 411
30. H.E. Lebovitz a-Glucosidase inhibitors as agents in the treatment of diabetes Diabetes Rev. 6 1998 132 145
31. A.H. Lichtenstein, L.J. Appel, M. Brands, M. Carnethon, S. Daniels, H.A. Franch, B. Franklin, P. Kris-Etherton, W.S. Harris, B. Howard, N. Karanja, M. Lefevre, L. Rudel, F. Sacks, L. Van Horn, M. Winston, and J. Wylie-Rosett Summary of American Heart Association diet and lifestyle recommendations revision 2006 Arterioscler. Thromb. Vasc. Biol. 26 2006 2186 2191
32. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
33. G.D. Norata, L. Grigore, S. Raselli, L. Redaelli, A. Hamsten, F. Maggi, P. Eriksson, and A.L. Catalano Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies Atherosclerosis 193 2007 321 327
34. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
35. E.J. Parks Recent findings in the study of postprandial lipemia Curr. Atheroscler. Rep. 3 2001 462 470
36. K. Peter, U. Weirich, T.K. Nordt, J. Ruef, and C. Bode Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis Thromb. Haemost. 82 1999 38 43
37. J.L. Petersen, and D.K. McGuire Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management Diab. Vasc. Dis. Res. 2 2005 9 15
38. N. Rifai, R.P. Tracy, and P.M. Ridker Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin. Chem. 45 1999 2136 2141
39. L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jönsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lindgren, Q. Qiao, S.G. Priori, J.J. Blanc, A. Budaj, J. Camm, V. Dean, J. Deckers, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J. Tamargo, J.L. Zamorano, J.W. Deckers, M. Bertrand, B. Charbonnel, E. Erdmann, E. Ferrannini, A. Flyvbjerg, H. Gohlke, J.R. Juanatey, I. Graham, P.F. Monteiro, K. Parhofer, K. Pyörälä, I. Raz, G. Schernthaner, M. Volpe, D. Wood Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. 28 2007 88 136
40. A. Silveira, F. Karpe, M. Blombäck, G. Steiner, G. Walldius, and A. Hamsten Activation of coagulation factor VII during alimentary lipemia Arterioscler. Thromb. 14 1994 60 69
41. M. Song, and J.A. Kellum Interleukin-6 Crit. Care Med. 33 2005 S463 S465
42. M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, and A. Sekikawa Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study Diab. Care 22 1994 920 924
43. W.C. Tsai, Y.H. Li, C.C. Lin, T.H. Chao, and J.H. Chen Effects of oxidative stress on endothelial function after a high-fat meal Clin. Sci. 106 2004 315 319
44. A.W. Wahlefeld Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis 2nd English Ed 1974 Academic Press., Inc New York 18 31
45. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diab. Care 27 2004 1487 1495
46. B.J. Winer Statistical Principles in Experimental Design 2nd Ed. 1971 McGraw-Hill New York
47. A.M. Witkowska, and M.H. Borawska Soluble intercellular adhesion molecule-1 (sICAM-1): an overview Eur. Cytokine Netw. 15 2004 91 98
48. T.P. Zwacka, V. Hornbach, and J. Torzewski C-reactive protein-mediated lipoprotein uptake by macrophages Circulation 103 2001 1194 1197